Any current/future new fundraising through debt or equity?

No specific mention of any current or planned fundraising through debt or equity in the transcript. Capital expenditure (capex) planned for FY '26 is around INR 110 crores, implying funding will likely come from internal accruals or existing resources. No explicit details provided about raising funds externally via debt or equity. Focus appears to be on organic growth, capacity expansion, and selective capex rather than on external fundraising. Management has not provided guidance or statements related to new fundraising activities in the disclosed Q1 FY '26 earnings call.

Any current/future capex/capital investment/strategic investment?

FY '26 capex plan is about INR 110 crores. New greenfield facility planned at Jolva to support additional capex for agro intermediate production. Minor capex under consideration for modifications and automation in semiconductor chemical production to move from pilot to plant scale. Additional capex expected for expanding electrolyte segment capacity, especially for supercapacitor and hybrid vehicle batteries requiring ultra-dry/ultra-pure handling and closed systems. Potential further expansions and automation anticipated for semiconductor and electrolyte businesses as volumes grow. Capex deci

Future growth expectations in sales/revenue/volumes?

Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025. SDA (Structure Directing Agents) segment revenues anticipated to grow with better margin realization, supported by near full plant capacity utilization. Electrolyte salts segment projected to contribute roughly 10% to the top line by FY 26-27, with significant volume growth (~200% growth mentioned). PASC (Pharma & Agro and Specialty Chemicals) segment gaining traction, expected to be a significant revenue contributor in FY 26 and beyond. Semiconductor segment starting commercialization with full-scale expected by 2029, sho

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '26 revenue growth guidance: ~25% compared to FY '25. FY '26 EBITDA margin guidance: ~20%, improving from ~15% in Q1. Margin expansion expected mainly in H2 of FY '26; exit run rate margin likely higher than 20%. Electrolyte segment expected to contribute about 10% of revenue by FY '26/'27. Capex plan for FY '26: approximately INR 110 crores to support growth and new product lines. R&D spend: around 1-1.5% of revenue (~INR 4-5 crores). SDA prices believed to have bottomed out; future growth anticipated. Electrolyte business expected to reach peak revenue of about INR 100 crores at optimal u

Current/ Expected Orderbook/ Pending Orders?

The company has high confidence in order execution with clear visibility of orders till at least December 2025. Most of the orders are already on hand, ensuring no uncertainty regarding near-term order fulfillment. Bulk orders in the PASC (Phase Transfer Catalyst) segment are set to commence supplies from early 2026. New orders and approvals in the electrolyte segment, including batteries for hybrid vehicles, indicate growing demand and commercial traction. There is clear visibility of significant orders ramping up in Q2 and Q3 of FY '26. Orders include those for new product launches expected

IN US

Sale is live|00:00:00left today

Tatva Chintan Pharma Chem LtdQ2 FY25Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,194P/E: 73.2Market Cap: ₹3.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025.
→SDA (Structure Directing Agents) segment revenues anticipated to grow with better margin realization, supported by near full plant capacity utilization.
→Electrolyte salts segment projected to contribute roughly 10% to the top line by FY 26-27, with significant volume growth (~200% growth mentioned).
→PASC (Pharma & Agro and Specialty Chemicals) segment gaining traction, expected to be a significant revenue contributor in FY 26 and beyond.
→Semiconductor segment starting commercialization with full-scale expected by 2029, showing promising long-term potential.
→Addressable market in SDA estimated at around 20% currently, with further volume increases planned.
→Capacity expansions and new large agro intermediate orders to support next year’s growth.
→Overall cautious optimism on export market recovery and demand revival from key customers in coming quarters.

Margin guidance

Category 3

→FY '26 revenue growth guidance: ~25% compared to FY '25.
→FY '26 EBITDA margin guidance: ~20%, improving from ~15% in Q1.
→Margin expansion expected mainly in H2 of FY '26; exit run rate margin likely higher than 20%.
→Electrolyte segment expected to contribute about 10% of revenue by FY '26/'27.
→Capex plan for FY '26: approximately INR 110 crores to support growth and new product lines.
→R&D spend: around 1-1.5% of revenue (~INR 4-5 crores).
→SDA prices believed to have bottomed out; future growth anticipated.
→Electrolyte business expected to reach peak revenue of about INR 100 crores at optimal utilization.
→Medium-term (FY '27/'28) growth outlook not formally guided; to be discussed offline.
→Semiconductor segment commercialization anticipated by 2029 with volumes starting ramp-up around 2027.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any current or planned fundraising through debt or equity in the transcript.
→Capital expenditure (capex) planned for FY '26 is around INR 110 crores, implying funding will likely come from internal accruals or existing resources.
→No explicit details provided about raising funds externally via debt or equity.
→Focus appears to be on organic growth, capacity expansion, and selective capex rather than on external fundraising.
→Management has not provided guidance or statements related to new fundraising activities in the disclosed Q1 FY '26 earnings call.

Order book

Yes

→The company has high confidence in order execution with clear visibility of orders till at least December 2025.
→Most of the orders are already on hand, ensuring no uncertainty regarding near-term order fulfillment.
→Bulk orders in the PASC (Phase Transfer Catalyst) segment are set to commence supplies from early 2026.
→New orders and approvals in the electrolyte segment, including batteries for hybrid vehicles, indicate growing demand and commercial traction.
→There is clear visibility of significant orders ramping up in Q2 and Q3 of FY '26.
→Orders include those for new product launches expected from Q3 FY '26 and beyond.
→Large customer contracts are anticipated to start supplying from early 2026, contributing significantly to volume growth.

Capex plans

Yes

→FY '26 capex plan is about INR 110 crores.
→New greenfield facility planned at Jolva to support additional capex for agro intermediate production.
→Minor capex under consideration for modifications and automation in semiconductor chemical production to move from pilot to plant scale.
→Additional capex expected for expanding electrolyte segment capacity, especially for supercapacitor and hybrid vehicle batteries requiring ultra-dry/ultra-pure handling and closed systems.
→Potential further expansions and automation anticipated for semiconductor and electrolyte businesses as volumes grow.
→Capex decisions for semiconductor scale-up will depend on successful pilot runs and customer validations.
→Overall, capex will support growth in SDA, PASC (Pharma & Agro Specialty Chemicals), semiconductor purity chemicals, and electrolyte battery segments.

How does Tatva Chintan Pharma Chem Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Tatva Chintan Pharma Chem Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Tatva Chintan Pharma Chem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio